Clinical trials of intracoronary urokinase

Clinical trials of intracoronary urokinase and meta-analysis are available for the following clinical conditions:

acute coronary syndrome

acute coronary syndrome, myocardial revascularization, all type of patients

intracoronary urokinase vs placebo : TAUSA, 1994 -

acute coronary syndrome, fibrinolysis, all type of patients

intracoronary urokinase vs placebo : TAUSA, 1994 -

Entry terms: Urokinase Type Plasminogen Activator, Urokinase-Type Plasminogen Activator, Urokinase Type Plasminogen Activator, Plasminogen Activator, Urokinase-Type, U-Plasminogen Activator, U Plasminogen Activator, U-PA, Urinary Plasminogen Activator, Urokinase, Renokinase, Abbokinase, Kidney Plasminogen Activator, Single-Chain Urokinase-Type Plasminogen Activator, Single Chain Urokinase Type Plasminogen Activator, Receptors, Urokinase Plasminogen Activator, CD87 Antigen, Antigen, CD87, Plasminogen Activator Receptor, Urokinase Type, Plasminogen Activator, Urokinase Receptor, Plasminogen Activator, Urokinase Receptors, Receptor, Urokinase Plasminogen Activator, U-PA Receptor, Receptor, U-PA, U PA Receptor, Upar Receptor, Receptor, Upar, Urokinase Plasminogen Activator Receptors, Urokinase-Type Plasminogen Activator Receptors, Urokinase Type Plasminogen Activator Receptors, Antigens, CD87, CD87 Antigens, Receptor, Pro-Urokinase, Pro-Urokinase Receptor, Receptor, Pro Urokinase, Plaur protein, mouse, plasminogen activator, urokinase receptor, mouse, CD87 antigen, mouse, urokinase-type plasminogen activator receptor, mouse, PLAUR protein, human, plasminogen activator, urokinase receptor, human, urokinase plasminogen activator surface receptor, human, CD87 antigen, human, M23 urokinase, rscu-PA-40 kDa-Hir, urokinase M23, saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase, Rescupase, A-74187, urokinase-converting protease, urokinase cofactor, Plaur protein, rat, plasminogen activator, urokinase receptor, rat, CD87 antigen, rat, acetyl-lysyl-prolyl-seryl-seryl-prolyl-prolyl-glutamyl-glutamic acid amide, urokinase plasminogen activator (136-143), human, A6 peptide, Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH2, Ac-KPSSPPEE-NH2, Mrc2 protein, mouse, urokinase plasminogen activator receptor-associated protein, mouse, Endo180 protein, mouse, mannose receptor, C type 2 protein, mouse, uPARAP-Endo180, mouse, uPARAP protein, mouse, diphtheria toxin-urokinase fusion protein, human, DTAT fusion protein, human, cyclo(19,31)-urokinase-type plasminogen activator (19-31), cyclo(19,31)-uPA(19-31), cyclo(19,31)(D-Cys)-uPA(19-31), glycyl-histidyl-arginyl-prolyl-single-chain urokinase-type plasminogen activator (144-411), GHRP-scu-PA-32K, Gly-His-Arg-Pro-scu-PA-32K, MRC2 protein, human, mannose receptor, C type 2 protein, human, uPARAP protein, human, uPAR-associated protein, human, urokinase-type plasminogen activator receptor-associated protein, human, KIAA0709 protein, human, mannose receptor, C type 2, human, urokinase-fibrinogen conjugate, U-F conj, urokinase-ATF-SAP-3, recombinant, ATF-SAP protein, recombinant, urokinase-type plasminogen activator (6-135), u-PA amino-terminal fragment (6-135), u-PA ATF (6-135), u-PA (6-135), urokinase A chain 149-157, urokinase-type plasminogen activator (17-34), U-PA (17-34), plasmin heavy chain-urokinase conjugate, PHC-UK, urokinase inhibitor